A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. Academic Article uri icon

Overview

abstract

  • We have recently reported that nicotine has angiogenic effects, which appear to be mediated through non-neuronal nicotinic acetylcholine receptors (nAChRs). Here, we describe the endogenous cholinergic pathway for angiogenesis. In an in vitro angiogenesis model, increasing concentrations of the nonselective nAChR antagonist mecamylamine completely and reversibly inhibited endothelial network formation. Although several nAChR isoforms are expressed on endothelial cells (ECs), a similar inhibition was only obtained with the selective alpha7-nAChR antagonist alpha-bungarotoxin, whereas other selective antagonists did not result in significant inhibition of network formation. alpha7-nAChR was upregulated during proliferation, by hypoxia in vitro, and by ischemia in vivo. The nAChR-induced network formation was partially dependent on VEGF, was completely dependent on the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways, and finally resulted in NF-kappaB activation. In vivo, pharmacological inhibition of nAChR as well as genetic disruption of alpha7-nAChR expression significantly inhibited inflammatory angiogenesis and reduced ischemia-induced angiogenesis and tumor growth. Our results suggest that nAChRs may play an important role in physiological and pathological angiogenesis. To our knowledge, this is the first description of a cholinergic angiogenic pathway, and it suggests a novel avenue for therapeutic modulation of angiogenesis.

publication date

  • August 1, 2002

Research

keywords

  • Endothelium, Vascular
  • Neovascularization, Pathologic
  • Neovascularization, Physiologic
  • Receptors, Nicotinic

Identity

PubMed Central ID

  • PMC150415

Scopus Document Identifier

  • 0036677593

Digital Object Identifier (DOI)

  • 10.1172/JCI14676

PubMed ID

  • 12189247

Additional Document Info

volume

  • 110

issue

  • 4